Urine levels of matrix metalloproteinases and their inhibitors as the marker of activity of chronic glomerulonephritis


如何引用文章

全文:

详细

MMP-2, MMP-9, TIMP-2, PAI-1, nephroscelrosis, chronic glomerulonephritis,
Urinary excretion matrix metalloproteinase (ММP-2 and ММP-9), tissue inhibitor MMP (ТIМP-2) and inhibitor of plasminogen type 1 activator (PAI-I) was investigated. Patients with chronic glomerulonephritis (CG) (I group (n=23) - CG with proteinuria of subnephrotic range (SNPU), II group (n=26) - CG with nephrotic syndrome (NS), III group (n=22) - CG with advanced proteinuria (PU) and transient renal failure (RF), IV group (n=15) - CG with high PU and permanent RF). With increasing of CG activity (advanced MS, NS appearance, acute nephritic syndrome development) we found relatively balanced increase of MMP, TIMP and PAI-I urine levels. In group of patients with permanent RF decrease of MMP urine excretion and acute increase of PAI-I concentration in the urine were found. The level of MMP and TIMP urine excretion at patients with progressive CG straightly correlated with 24-h PU level and inversely correlated with serum creatinine level. Conclusion: changes in MMP, TIMP and PAI-1 urinary excretion levels can be used as a marker of kidney disease activity and severity in chronic glomerulonephritis

参考

  1. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274(31):21491-94.
  2. Gomes DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74(2):111-22.
  3. Eddy AА. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002;283(2):209-20.
  4. Сatania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007;292:905-11.
  5. Sanders J-SF, Goor H, Hanemaaijer R, et al. Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis. Nephrol Dial Transplant 2004;19:1412-19.
  6. Akiyama K, Shikata K, Sugimoto H, et al. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitor of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res Commun Mol Pathol Pharmacol 1997;95:115-28.
  7. Mc Millan JI, Riordan JW, Couser WG, et al. Characterisation of a glomerular epithelial cell matrix metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest 1996;97:1094-101.
  8. Sanders J-SF, Huitema М, Hanemaaijer R, et al. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. Am J Physiol Renal Physiol 2007;293:1927-34.
  9. Lods N, Ferrari P, Frey FJ, et al. Angiotensin-converting enzyme inhibition but not angiotensin receptor blockade regulates matrix metalloproteinases activity in patients with glomerulonephritis. J Am Soc Nephrol 2003;14:2861-72.
  10. Hörstrup JH, Gehrmann M, Schneider B, et al. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol Dial Transplant 2002;17:1005-13.
  11. Мухин Н.А., Козловская Л.В., Бобкова И.Н. и др. Ключевая роль ремоделирования тубулоинтерстиция в прогрессировании хронических заболеваний почек // Архив патологии. 2004. № 6. С. 16-22.
  12. Козловская Л.В., Бобкова И.Н., Плиева О.К. и др. Значение исследования в моче молекулярных медиаторов иммунного воспаления и фиброза в почке при хроническом гломерулонефрите // Терапевтический архив. 2004. № 9. С. 84-87.
  13. Бобкова И.Н., Козловская Л.В., Чеботарева Н.В. Мочевые тесты воспаления и фиброза в оценке прогрессирования хронического гломерулонефрита // Качество жизни. 2006. № 4. С. 19-25.
  14. Бобкова И.Н., Чеботарева Н.В., Козловская Л.В. и др. Экскреция с мочой моноцитарного хемотаксического протеина-1 и трансформирующего фактора роста-ß1 как показатель прогрессирования хронического гломерулонефрита // Терапевтический архив. 2006. № 5. С. 9-14.
  15. Ng YY, Huang TP, Yang WC. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998;54:864-76.
  16. Cheng S, Pollock AS, Mahimkar R, et al. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 2006;20:1898-900.
  17. Cheng S, Lovett D. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 2003;162:1937-49.
  18. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res 2003;92:827-39.
  19. Oda T, Jung YO, Kim HS, et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 2001;60:587-96.
  20. Rondeau E, Ochi S, Lacave R, et al. Urokinase synthesis and binding by glomerular epithelial cells in culture. Kidney Int 1989;36:593-600.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##